BioViva is opening its research facility in the United Kingdom to do the following:
Develop vector technology
Identify and select novel promoters
Test gene therapies in vitro
Optimize gene therapy production and costs
Our Research Pipeline
We are exploring the transient expression of pluripotency factors for age reversal, through targeted mRNA infusion.
We are exploring an intramuscular gene editing strategy to modulate myostatin expression for the treatment of sarcopenia.
OPTIMIZED FOLLISTATIN mRNA
In addition to our initial gene therapy approach for sarcopenia, we are developing an optimized follistatin mRNA platform with self replicating technology to maximize treatment duration and efficacy.
NEXT GENERATION hTERT mRNA
Our research team is improving on our original telomerase gene therapy by offering a stable mRNA treatment for enhanced expression and rejuvenation.
SENESCENT CELL CLEARANCE
We are researching a unique senolytic strategy involving targeting of cellular senescence markers - leading to the specific destruction of these cells without harming healthy tissue.